NCT00059930 2025-03-26
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Clinical Trials
11 trialsNCT00591123 2021-10-01
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Phase 2 Completed
NCT00006050 2021-02-17
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
UNICANCER
Phase 2 Completed
NCT03031444 2021-02-01
PARECEC
Peking University Cancer Hospital & Institute
Phase 2/3 Completed
NCT01490996 2020-01-31
CUFOX
University of Leicester
Phase 1/2 Completed
NCT00440310 2015-08-25
Phase 3 Trial of Litxâ„¢ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Light Sciences Oncology
Phase 3 Completed
NCT01030042 2015-07-15
COMETS
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase 3 Completed
NCT00494221 2014-03-27
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
Phase 1/2 Completed
NCT00103298 2013-06-20
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00008294 2013-01-18
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00116506 2007-12-21
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed